NovoCure
NVCR
308 hedge funds and large institutions have $6.79B invested in NovoCure in 2022 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 94 increasing their positions, 114 reducing their positions, and 51 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
14% more capital invested
Capital invested by funds: $5.94B → $6.79B (+$855M)
1.97% more ownership
Funds ownership: 76.17% → 78.14% (+2%)
2% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 51
1% less funds holding
Funds holding: 311 → 308 (-3)
18% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 114
25% less call options, than puts
Call options by funds: $78.1M | Put options by funds: $104M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$216M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$46.2M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$33.1M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$19M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$23.2M |
| 2 |
Two Sigma Investments
New York
|
-$21.1M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$20.2M |
| 4 |
DCP
Darsana Capital Partners
New York
|
-$19.4M |
| 5 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$18.3M |
NVCR Hedge Fund Activity: Q1 2022 in Review
308 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2022, worth a combined $6.79B — up 14% from $5.94B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new NVCR positions and 51 closed out — a net gain of 1 holder — while 94 added to existing stakes and 114 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $216M. The largest seller was Macquarie Group, cutting an estimated $23.2M.
- 308 institutional investors held NovoCure (NVCR) as of Q1 2022, down from 311 in Q4 2021.
- Funds reported $6.79B of NovoCure stock for Q1 2022, up 14% quarter-over-quarter.
- 52 funds opened new NovoCure positions in Q1 2022 and 51 closed out, a net change of +1 holder.
- The largest NovoCure buyer in Q1 2022 was Fidelity Investments, an estimated $216M added.
- The largest NovoCure seller in Q1 2022 was Macquarie Group, an estimated $23.2M sold.
Based on aggregated 13F filings for Q1 2022.